Ann: Response to ASX Price Query, page-89

Yes, phase 3 trials will attract a 3rd party for funding purposes. However - not all the time. Only 20% are fully funded by sponsors - though other external funding sources may get involved.

So, we can't say it happens all the time. Having said that, BIT is doing HIV trials and, if these turn out to be brilliant, they should get some external funding for phase 3 trials

Phase 3 clinical trials, which play a crucial role in evaluating the safety and efficacy of new medical interventions, can indeed receive funding from various sources. Let’s explore this further:

1. Academic Sponsors: A significant proportion of clinical trials, including Phase 3 trials, are initiated and funded by academic entities. These sponsors often collaborate with researchers, institutions, and experts to conduct rigorous studies¹.

2. National Institutes of Health (NIH): The NIH, a prominent U.S. government agency, provides funding for clinical trials. However, its contribution constitutes a smaller percentage of overall trial funding¹.

3. Industry Funding: Pharmaceutical companies and other industry players also contribute to clinical trial funding. Approximately 20% of trials receive financial support from industry sources¹.

4. External Entities: In some cases, an independent external entity (not directly affiliated with the sponsor) may perform analyses or provide information to the sponsor. This external body can play a role in funding or supporting the trial.

In summary, while academic sponsors are common funders of Phase 3 trials, a mix of sources—including academic institutions, industry, and external entities—can contribute to their financial support. The ultimate goal is to advance medical knowledge and improve patient care through well-designed and adequately funded research.